Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The Company bases its approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.